The effects of tamoxifen on radiation-induced pulmonary fibrosis in Wistar albino rats: Results of an experimental study

被引:22
作者
Bese, Nuran Senel [1 ]
Umay, Cenk [1 ]
Yildirim, Sukru [2 ]
Ilvan, Sennur [3 ]
Dirican, Ahmet
Salar, Seda [4 ,5 ]
Altug, Tuncay [6 ]
Ober, Ahmet [1 ]
机构
[1] Istanbul Univ, Cerrahpasa Med Sch, Dept Radiat Oncol, Istanbul, Turkey
[2] GATA Haydarpasa Training Hosp, Dept Pathol, Istanbul, Turkey
[3] Istanbul Univ, Cerrahpasa Med Sch, Dept Pathol, Istanbul, Turkey
[4] Istanbul Univ, Cerrahpasa Med Sch, Dept Biostat, Istanbul, Turkey
[5] Istanbul Univ, Cerrahpasa Med Biol Sch, Istanbul, Turkey
[6] Istanbul Univ, Cerrahpasa Med Sch, Dept Expt Anim Breeding & Res Lab, Istanbul, Turkey
关键词
pulmonary fibrosis; tamoxifen; irradiation; rats;
D O I
10.1016/j.breast.2005.04.016
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
This study was performed to evaluate the effects of tamoxifen on pulmonary fibrosis, given concurrently with or after irradiation in Wistar albino rats. Twenty-one female Wistar albino rats were randomized into three groups. The first group (Group A) had tamoxifen, which was started after the completion of irradiation. The second group (Group B) had tamoxifen concomitant with irradiation. The third group (Group C) had only thoracic irradiation and did not receive tamoxifen. Whole lungs were irradiated to a total dose of 30 Gy in ten fractions with Co60. Tamoxifen was continued until the animals were sacrificed 16 weeks after the start of irradiation. As an end point the percentage of lung with fibrosis for each rat was quantified with image analysis of histological sections of the lung. Groups were compared using the one-way ANOVA method and Bonferroni post hoc test. The mean percentage values of fibrosis were 10.03 for Group A, 36.81 for Group B, and 3.87 for group C (P < 0.001). When the percentages of fibrosis were compared for each group, the difference was statistically significant between Group A and Group B (P < 0.001) and between Group B and Group C (P < 0.001). Concomitant use of tamoxifen appears to increase radiation-induced pulmonary fibrosis and it seems more convenient to delay tamoxifen until the completion of irradiation. (C) 2005 Elsevier Ltd. All rights reserved.
引用
收藏
页码:456 / 460
页数:5
相关论文
共 20 条
[1]   Plasma transforming growth factor β1 as a predictor of radiation pneumonitis [J].
Anscher, MS ;
Kong, FM ;
Andrews, K ;
Clough, R ;
Marks, LB ;
Bentel, G ;
Jirtle, RL .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1998, 41 (05) :1029-1035
[2]   Concomitant use of tamoxifen with radiotherapy enhances subcutaneous breast fibrosis in hypersensitive patients [J].
Azria, D ;
Gourgou, S ;
Sozzi, WJ ;
Zouhair, A ;
Mirimanoff, RO ;
Kramar, A ;
Lemanski, C ;
Dubois, JB ;
Romieu, G ;
Pelegrin, A ;
Ozsahin, M .
BRITISH JOURNAL OF CANCER, 2004, 91 (07) :1251-1260
[3]   Radiotherapy-related lung fibrosis enhanced by tamoxifen [J].
Bentzen, SM ;
Skoczylas, JZ ;
Overgaard, M ;
Overgaard, J .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1996, 88 (13) :918-922
[4]  
BENTZEN SM, 1994, ADV RADIAT BIOL, V18, P25
[5]  
BORDER WA, 1994, NEW ENGL J MED, V331, P1286
[6]  
Brandt S, 2003, ANTICANCER RES, V23, P223
[7]   Radiation pneumonitis and early circulatory cytokine markers [J].
Chen, YY ;
Williams, J ;
Ding, I ;
Hernady, E ;
Liu, WM ;
Smudzin, T ;
Finkelstein, JN ;
Rubin, P ;
Okunieff, P .
SEMINARS IN RADIATION ONCOLOGY, 2002, 12 (01) :26-33
[8]   ANTIESTROGENS INDUCE THE SECRETION OF ACTIVE TRANSFORMING GROWTH-FACTOR-BETA FROM HUMAN FETAL FIBROBLASTS [J].
COLLETTA, AA ;
WAKEFIELD, LM ;
HOWELL, FV ;
VANROOZENDAAL, KEP ;
DANIELPOUR, D ;
EBBS, SR ;
SPORN, MB ;
BAUM, M .
BRITISH JOURNAL OF CANCER, 1990, 62 (03) :405-409
[9]  
Daniel WW., 1995, BIOSTATISTICS FDN AN, P273
[10]   The impact of tamoxifen on breast recurrence, cosmesis, complications, and survival in estrogen receptor-positive early-stage breast cancer [J].
Fowble, B ;
Fein, DA ;
Hanlon, AL ;
Eisenberg, BL ;
Hoffman, JP ;
Sigurdson, ER ;
Daly, MB ;
Goldstein, LJ .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1996, 35 (04) :669-677